



## Corium to Report First Quarter Fiscal 2018 Financial Results on Thursday, February 8, 2018

February 1, 2018

MENLO PARK, Calif., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the first quarter ended December 31, 2017 on February 8, 2018 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress.

### Conference Call and Webcast Details

Investors and analysts can access the conference call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 7046249. The conference call will also be available via a live audio webcast which may be accessed [here](#), or by visiting the Investors section of Corium's website at <http://ir.coriumgroup.com/events-and-presentations>. The webcast will be archived on the Corium website for two weeks following the presentation.

### About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit [www.coriumintl.com](http://www.coriumintl.com).

Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.

Source: Corium

Investor and Media Contact:  
SMP Communications  
Susan Pietropaolo  
[spietropaolo@bccpartners.com](mailto:spietropaolo@bccpartners.com)  
(201) 923-2049

 [Primary Logo](#)

Source: Corium International, Inc.